CED, aforetime the Council for Entrepreneurial Development (www.cednc.org), a private, nonprofit alignment that promotes ambitious efforts in the Triangle arena of North Carolina, has appear that it will host the next chapter of its accepted STREAK program, to be captivated Thursday, Dec. 10 from 3 p.m. to 5 p.m. STREAK is advised to abetment early-stage, high-growth activity sciences and technology companies in advancing for and extensive fundraising goals through the appraisal of angle presentations by a acclimatized console of investors, entrepreneurs and business experts.
Presenters at the academy cover Richard Shea, CEO of Vascular Pharmaceuticals and Timothy Klapish, COO of PhytoChem Pharmaceuticals (www.phytochem.com). Panelists cover Phillipa Charlton, M.D. MPH, medical administrator at Tranzyme Pharma; Clayton Duncan, admiral and CEO of Vindica Therapeutics; Christopher Humprey, accomplice at Alston & Bird LLP; Charles Osborne, CFO at Scynexis Inc.; Tom Roberg, CEO and controlling administrator at LAAM Sciences Inc.; Scott Weiner, arch at Pappas Ventures; and William Wofford, accomplice at Hutchison Law Group.
STREAK is a closed-door affair befalling that is alone accessible to CED associates and takes abode on the additional Thursday afternoon of anniversary month. Of the 12 companies called to present afore the panels, CED will baddest the a lot of notable presenters to advertise at a January event. For data on access belief and the appliance process, CED associates should e-mail their business plan and added accordant advice to affairs coordinators Bob Pickens at bpickens@cednc.org or Dhruv Patel at dpatel@cednc.org.
QUOTES:
“We are aflame to accept PhytoChem and Vascular Pharmaceuticals, two cutting-edge biologic companies, present at our December STREAK seminar,” said Bob Pickens, administrator of entrepreneurship at CED. “The STREAK affairs will acquiesce them the adventitious to crop their companies to the next date and add to their approaching success.”
NEW MEDIA CONTENT:
CED blog http://cednc.wordpress.com
CED Twitter page http://twitter.com/CEDNC
DETAILS:
- Vascular Pharmaceuticals is focused on the development and commercialization of atypical ameliorative articles for the analysis of cardiovascular and metabolic complications accompanying to diabetes.
- The above focus of the Vascular Pharmaceuticals is advancing the advance affairs in diabetic atherosclerosis into animal analytic trials in backward 2011.
- PhytoChem Pharmaceuticals is a growing biologic close focused on analysis of accustomed compounds targeted at cardiovascular, cancer, and dermatological conditions.
- One of CED’s a lot of accepted and admired offerings, STREAK provides associates the befalling to abide their business plan and broker angle for application to present afore a custom-built able panel. The panelists are best to abode the specific needs of anniversary aggregation by accouterment acknowledgment on strategy, business advice, allotment options and added accordant contacts. STREAK is sponsored by Hutchison Law Group and Hughes Pittman & Gupton, LLP.
ABOUT CED:
CED (formerly The Council for Entrepreneurial Development) is a private, nonprofit alignment founded in 1984 to identify, accredit and advance high-growth, high-impact companies and advanced the region’s ambitious culture. Headquartered in the Research Triangle Park, CED is the oldest and better ambitious abutment alignment in the nation with added than 5,500 breath members. CED provides know-how, networking, mentoring and basic accumulation assets to new and absolute high-growth entrepreneurs through anniversary conferences, programs and web-based resources. CED has helped entrepreneurs, investors, account partners, advisers and accessible action makers in assorted arising industries and at all stages of development – from high-tech, production-based organizations to account companies, from one-person start-ups to 1000-person businesses. Visit www.cednc.org for added information.
Jake Potter
MMI Public Relations
(919) 233-6600
jake@mmipublicrelations.com http://twitter.com/MMIPR
www.mmipublicrelations.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment